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Background: Depression is one of the most common neuropsychiatric complications of HIV disease, and in turn it
is associated with worse HIV-related outcomes. Data on depression among HIV-infected patients in Cameroon are
scarce. In this study, we report the prevalence and correlates of depressive symptoms among newly diagnosed
HIV-infected patients in Yaoundé, Cameroon.
Methods: Interviews were conducted with 100 newly diagnosed HIV-infected patients at three referral hospitals of
Yaoundé. Depression was assessed using the nine-item Patient Health Questionnaire (PHQ-9). A positive depression
screen was defined as PHQ-9 score greater than 9.
Results: The overall prevalence of depressive symptoms was 63% (95% CI: 53.2 to 71.8), the majority having
symptoms corresponding to moderate depression. Multiple logistic regression analysis showed that probable
depressed patients were more likely than those who were not depressed to have had experience of alcohol abuse
(OR: 19.03, 95% CI 3.11-375.85; p = 0.0083), and a 100 CD4 cells/mm3 fewer was associated with a 2.9 times increase
of the odds of probable depression (95% CI 1.88-4.84; p < 0.0001).
Conclusions: Our findings indicate a high prevalence of depressive symptoms in newly diagnosed HIV-infected
patients in our setting, and their association with alcohol abuse and severe immunosuppression. This study also
highlights the necessity to integrate mental health interventions into routine HIV clinical care in Cameroon.
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The HIV/AIDS pandemic has caused far-reaching effects
in low-income countries. Sub-Saharan Africa has been
particularly hard hit. In 2010, 68% of all people living
with HIV resided in Sub-Saharan Africa, a region with
only 12% of the global population [1]. Sub-Saharan Af-
rica also accounted for 70% of new HIV infections and
67% of AIDS-related deaths in 2010 [1].* Correspondence: noubiapjj@yahoo.fr
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reproduction in any medium, provided the orCameroon is one of the 22 priority countries in the World
Health Organization’s Global Plan towards the Elimination
of New HIV Infections among Children and Keeping Their
Mothers Alive [2]. Situated in the Central Africa, Cameroon
has the largest HIV/AIDS epidemic in this sub-region with
an estimated HIV prevalence of 5.3%, 610,000 people living
with HIV, 48,000 adults newly infected and 37,000 AIDS-
related deaths reported in 2009 [3].
Depression is the most common neuropsychiatric compli-
cation of HIV disease [4]. HIV/AIDS and depression are
projected to be the world’s two leading causes of disability by
2030 [5]. Reports on the actual prevalence of depression in
HIV-infected persons have varied widely, from 22% [6] to
71% [7]. With 350 million people affected worldwide [8],
rates of depression are roughly two times greater in peopletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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10% versus 5%), as determined by a meta-analysis of pub-
lished studies [9]. Depression is associated with increased
health care utilization [10], decreased quality of life [11], and
increased suicide rate among patients in primary care [12].
Among people living with HIV/AIDS, depression increases
the likelihood of HIV transmission [13], is associated with
poor adherence to antiretroviral therapy (ART) [14] leading to
virologic failure [15], and may independently increase HIV
progression [16]. It is therefore crucial to identify patients with
depression for an appropriate management. Unfortunately in
Cameroon, the management of HIV/AIDS emphasizes on
somatic aspects of the disease and neglects psychiatric mani-
festations, and depression is therefore underdiagnosed. This is
essentially due to the fact that mental health is not effectively
integrated into HIV/AIDS clinical care.
A recent study among HIV-infected patients on ART in a
semi-urban centre in Cameroon reported that one in five
participants met lifetime criteria for major depression disor-
ders [17]. There are no other prior studies of depression
prevalence among HIV patients in Cameroon. Our study
aimed at determining the prevalence and correlates of de-
pressive symptoms among newly diagnosed HIV-infected
patients in Yaoundé, Cameroon.
Methods
Ethical considerations
This study was performed in accordance with the guidelines
of the Helsinki Declaration and was approved by the
National Ethics Committee of Cameroon (ethics approval
N°008/CNE/SE/2011). All participants provided written
informed consent.
Study design and setting
We conducted an observational cross-sectional study in
Yaoundé, Cameroon. Yaoundé is the administrative head-
quarters of the Centre Region and the political capital of the
Republic of Cameroon. It is one of the two largest cities of
Cameroon, with a population estimated at 2,000,000 inhabi-
tants and characterized by a very great ethnic diversity; with
almost all the 254 ethnic groups found in Cameroon repre-
sented [18].
The study was conducted between February and March
2011 in three HIV/AIDS treatment centers in Yaoundé
which are among the pioneers in the fight against HIV in-
fection in Cameroon. These centers are located in three re-
ferral hospitals: the Yaoundé Central Hospital that has the
greatest pool of HIV-infected patients in Yaoundé, the
Yaoundé Jamot Hospital that has the major centre for men-
tal health in Yaoundé, and the Yaoundé General Hospital.
Study population and sampling
The target population comprised of newly diagnosed HIV-
patients. To be eligible, patients had to be diagnosed HIV-positive within the past six months, aged 18 years or more,
speaking English or French and consenting to participate
in the study. We excluded patients presenting with behav-
ioral disorders that may impede the ability to answer the
study questionnaire. Participants were identified by con-
venient and consecutive sampling of eligible patients who
came for consultation on the days that the investigator
conducted recruitment at each site. Recruitment was pur-




Eleven background variables are: age, gender, education,
area of residency (urban or rural), marital status, employ-
ment status, personal history of depression, family history
of depression, alcohol abuse, last CD4 cell count and ART.
Screening for alcohol abuse
Alcohol abuse was diagnosed using the CAGE (Cutting
down, Annoyance by criticism, Guilty feelings, Eye-
openers) questionnaire [19]. This instrument includes
four questions: (i) Have you ever felt you should cut
down your drinking? (ii) Have people annoyed you by
criticizing your drinking? (iii) Have you felt bad or guilty
about your drinking? (iv) Have you ever had a drink first
thing in the morning to steady your nerves or get rid of
a hangover (eye-opener)? Alcohol abuse is diagnosed if
there are at least two positive responses. The CAGE has
been shown to have a sensitivity of 84.4% and a specifi-
city of 93.1% to detect alcohol-related problems at this
threshold of 2 positive responses [20].
Screening for depressive symptoms
Depression was assessed using the nine-item Patient Health
Questionnaire (PHQ-9), a validated depression screening
tool which is based on the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th Edition (DSM-IV) criteria
[21]. Depression severity is based on the PHQ-9 scores,
which ranges from 0 to 27. A PHQ-9 score of greater than
9 has a sensitivity of 83% and a specificity of 92% for major
depressive disorder diagnosis [22]. In this study, a positive
depression screen was defined as PHQ-9 score greater than
9; scores of 10 to 14 defined a moderate depression; scores
of 15 to 19 defined a moderately severe depression; scores
greater than 20 defined a severe depression. Some studies
have addressed the issue of using screening instruments
such as PHQ-9 to diagnose psychiatric disorder [23].
Therefore, given inability to report prevalence of depres-
sion, we report the prevalence of depressive symptoms.
Data analysis
Data were coded, entered and analyzed using the Statis-
tical Package for Social Science (SPSS) version 20.0 for
Table 1 Background characteristics of 100 newly
diagnosed HIV-positive patients in Yaoundé, Cameroon
Characteristic Male (n = 48) Female (n = 52) P-value
n (%) or mean (SD)
Age (years) 42.4 (10.3) 38.7 (10.3) 0.07
Marital status
Single 16 (33.3) 24 (46.2) 0.19
Couple 32 (66.7) 28 (53.8)
Education level
Primary 16 (33.3) 20 (38.5) 0.76
Secondary 17 (35.4) 19 (36.5)
University 15 (31.3) 13 (25)
Employment status
Employed 32 (66.7) 14 (27) < 0.001
Unemployed 16 (33.3) 38 (73)
Area of residence
Urban 33 (68.7) 43 (82.7) 0.10
Rural 15 (31.3) 9 (7.3)
Personal past history of depression
Yes 3 (6.3) 2 (3.8) 0.50
No 45 (93.7) 50 (96.2)
Family past history of depression
Yes 2 (4.2) 0 (0) 0.22
No 46 (95.8) 52 (100)
Alcohol abuse
Yes 8 (16.7) 9 (17.3) 0.93
No 40 (83.3) 43 (82.7)
Receive antiretroviral treatment
Yes 19 (39.6) 21 (40.4) 0.93
No 29 (50.4) 31 (59.6)
CD4 cells count (cells/mm3) 254 (116) 216 (139) 0.14
Table 2 Prevalence of depressive symptoms among 100
newly diagnosed HIV-positive patients in Yaoundé, Cameroon
Depression severity Frequency or percentage* 95% CI
No depression 37 28.2 – 46.8
Moderate depression 46 36.6 – 55.7
Moderately severe depression 16 10.1 – 24.4
Severe depression 1 0.2 – 5.4
* Since N = 100, frequencies and percentages are identical.
No depression: PHQ-9 scores less than 9; Moderate depression: scores of 10 to
14; Moderately severe depression: scores of 15 to 19; Severe depression:
scores greater than 20.
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quantitative variables using means with standard devia-
tions (SD), and categorical variables using their frequen-
cies and percentages. The t-test and the Chi-square test
were used to compare quantitative and categorical vari-
ables respectively. Odds ratios (OR) with 95% confidence
interval (CI) were used to evaluate the factors associated
with depressive symptoms. The unadjusted ORs were
calculated by univariate logistic regression. Furthermore,
multiple logistic regression analyses were conducted
based on five candidate models, which were compared
using Akaike Information Criterion (AIC). The optimal
model among the candidates is the one with the smallest
AIC score [24]. This manuscript was written following
STROBE guidelines for the reporting of observational
studies [25].
Results
Background characteristics of study population
Among the 100 newly diagnosed HIV-infected partici-
pants, 52% were female; their ages ranged from 18 to
62 years with a mean of 40.4 years (SD = 10.4). Their
CD4 cell counts ranged from 9 to 474 cells/mm3 with a
mean of 234 (SD = 129). Sixty percent were living with a
spouse, 54% were unemployed, and 76% were living in
an urban area. The CAGE alcoholism screen was posi-
tive in 17% of the participants. Thirty-nine percent of
participants had severe immunosuppression (CD4 cell
count < 200). Five percent had had a previous episode of
depression. Other characteristics are depicted in Table 1.
Prevalence and correlates of depression
As shown in Table 2, 63% (95% CI: 53.2 to 71.8) of our
study population had depressive symptoms, most of
them having symptoms corresponding to moderate de-
pression (46% of the entire sample, and 73% of the de-
pressed ones).
Table 3 presents unadjusted odds of depression with
those background characteristics. Under Bonferroni cor-
rection for multiple comparisons (i.e., using significance
level 0.05/11 = 0.0045), both alcohol abuse (p = 0.003)
and CD4 counts (p < 0.0001) are significantly associated
with probable depression. These results are confirmed by
logistic regression analyses summarized in Table 4. We
compared five candidates models (1: includes all variables;
2: includes all variables suspected in the literature; 3:
model 2 plus ART; 4: includes alcohol, CD4 cells count,
and gender; 5: includes only alcohol and CD4 cells count)
using Akaike Information Criterion (the smaller the bet-
ter). It appears that model 1 was over-fit because of the
largest AIC score associated with it. Moreover, the unusual
changes in OR estimates from model 1 to 2 and 3 suggest
that we should consider models sparser than model 1. It
seems model 5, including only alcohol and CD4, was thebest model among five candidates. Inference based on this
model showed that probable depressed patients were more
likely than those who were not depressed to have had ex-
perience of alcohol abuse (OR: 19.03, 95% CI 3.11-375.85;
p = 0.0083), and a 100 CD4 cells/mm3 fewer was asso-
Table 3 Unadjusted correlates of depressive symptoms among 100 newly diagnosed HIV-positive patients in Yaoundé,
Cameroon
Measure Total Depression n (%) OR (95% CI) P-value
Age (years) 100 - 0.99 (0.96 – 1.01) 0.34
Gender
Male 48 26 (54.2) Referent
Female 52 37 (71.1) 0.48 (0.19 – 1.18) 0.078
Marital status
Couple 60 38 (63.3) Referent
Single 40 25 (62.5) 0.96 (0.39 – 2.40) 0.93
Educational level
University 28 18 (64.3) Referent
Less than university 72 45 (62.5) 0.93 (0.34 – 2.51) 0.86
Employment status
Employed 46 29 (63) Referent
Unemployed 54 34 (63) 1.00 (0.41 – 2.44) 0.99
Area of residence
Urban 76 46 (60.5) Referent
Rural 24 17 (70.3) 1.58 (0.53 – 4.82) 0.36
Personal past history of depression
No 95 61 (64.2) Referent
Yes 5 2 (40) 0.37 (0.04 – 2.93) 0.26
Family past history of depression
No 98 62 (63.3) Referent
Yes 2 1 (50) 0.58 (0.03 – 9.57) 0.70
Alcohol abuse
No 83 47 (56.6) Referent
Yes 17 16 (94.1) 12.26 (1.57 – 259.21) 0.003
Antiretroviral treatment
No 60 35 (58.3) 0.60 (0.23 – 1.52)
Yes 40 28 (70) Referent 0.23
CD4 cells count* 100 - 2.7 (1.79 – 4.72) < 0.0001
* expressed by hundreds of cells/mm3. OR unadjusted odds ratio.
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pression (95% CI 1.88-4.84; p < 0.0001).
Discussion
Depression is a major problem in HIV-infected patients,
because it can lead to poor adherence to ART, treatment
failure, HIV progression and death [13-16]. Several years
ago, it had been prominently reported that mental health
must be integrated in global initiatives for HIV/AIDS,
and that research on mental health and HIV should be a
high priority, especially in less wealthy countries like
Cameroon [26]. Unfortunately, there is still a scarcity of
data on mental health in Cameroon. This study is only
the second one on depression in HIV-infected patients
in Cameroon. Accordingly, we sought to determine theprevalence and correlates of depressive symptoms among
newly diagnosed HIV-infected patients in Yaoundé,
Cameroon.
We found that 63% of our participants were probably
depressed. In similar studies, Ouedraogo et al., Kaharuza
et al. and Bhatia et al. respectively found depression
prevalence of 51.3% in Burkina Faso, 47% in Uganda and
45% in USA [27-29]. Collaborating with these reports,
our findings point out that depression is highly frequent
among newly diagnosed HIV-infected patients. This high
prevalence of depressive symptoms in our study popula-
tion may be due to several factors. First, it may be re-
flective of psychological distress, precisely an adjustment
reaction, due to recent notification of seropositivity.
Supporting this hypothesis, Lyketsos et al. found that




(1) (2) (3) (4) (5)
Age 1.03 (0.28) - - - -
CD4 cell count* 3.30 (< 0.0001) 2.85 (< 0.0001) 3.12 (< 0.0001) 2.85 (< 0.0001) 2.9 (< 0.0001)
Gender (male) 2.42 (0.23) 1.93 (0.27) 2.05 (0.24) 1.95 (0.20) -
Marital status (couple) 1.17 (0.78) 0.89 (0.83) 0.88 (0.82) - -
Educational level (university) 2.40 (0.24) - - - -
Employment status (employed) 0.49 (0.39) 1.06 (0.92) 0.95 (0.94) - -
Area of residence (urban) 2.25 (0.25) - - - -
Personal past history of depression (no) 0.55 (0.59) - - - -
Family past history of depression (no) 0.27 (0.61) - - - -
Alcohol abuse (no) 44.66 (0.003) 19.79 (0.01) 22.96 (0.0068) 20.0 (0.0084) 19.03 (0.0083)
Antiretroviral treatment (yes) 1.95 (0.28) - 1.82 (0.31) - -
AIC score 109.40 103.24 104.17 99.3 98.9
* expressed by hundreds of cells/mm3. OR adjusted odds ratio, AIC Akaike Information Criterion.
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psychiatric morbidity among newly diagnosed HIV-
patients in a medical outpatient HIV clinic [30]. On the
contrary, other studies have shown only a modest in-
crease in psychological distress immediately after notifi-
cation of seropositivity, suggesting that adjustment does
not play a major role in psychiatric morbidity at diagno-
sis of HIV infection [31]. Much more, Savetsky et al.
reported that 71% of an urban cohort were depressed a
mean of 840 days after diagnosis, which is beyond the
timeframe of adjustment [7].
The high prevalence of depressive symptoms in our study
may also be explained by severe immunosuppression in the
participants. Thirty-nine percent of participants had severe
immunosuppression (CD4 cell count < 200), and univariate
and multivariate logistic regression showed a significant as-
sociation between severe immunodepression and depressive
symptoms. Indeed, it has been shown that severe immuno-
depression and HIV-illness are predictors of depression
[32-34]. It is therefore crucial to adequately treat depression
in newly diagnosed HIV-patients to impact ART adherence
which will in turn enhance physical health and quality of
life and subsequently prevent long-term depression.
Seventeen percent of our participants were screened
positive for alcohol abuse during the past six months.
Consistent with previous reports [35], alcohol abuse
strongly correlates with depressive symptoms in our
study population. Factors such as unemployment and
single status have been shown to strongly contribute to
depression in HIV-patients [28,29,36]. In our study these
factors were not significantly associated with depressive
symptoms, emphasizing the great psychological burden
of the HIV status itself in our participants.Regardless of its correlates, the magnitude of probable
depression reported in our study emphasizes the need to
incorporate the management of depression in HIV-care
guidelines in Cameroon. In their study in Bamenda,
Cameroon, Gaynes et al. have reported that identifica-
tion and successful management of major depression by
a health care professional was infrequent [17]. Studies in
developing countries have shown that proper interven-
tions, including a cognitive-behavioral group plan and
community-driven group interpersonal psychotherapy,
can reduce depressive symptoms and may lead to a bet-
ter quality of life for patients with HIV or patients in re-
gions with a high prevalence of HIV [37,38].
This study has some limitations. First, the study was
conducted in an urban context, and patients from rural
areas were in fact from the accessible rural outskirts of
the town. Patients from isolated rural areas were not in-
cluded in this study, and the impact of the place of resi-
dence (rural or urban) on the occurrence of depression
was not well estimated. Secondly, the convenient sample
size of 100 may also imply imprecision in our findings.
However, our findings are consistent with several prior re-
ports in similar settings. In addition, our data are from
three referral centers for HIV/AIDS management and
mental health in Yaoundé, thus supporting their genera-
lizability especially in the urban context of Cameroon.
Thirdly, we used high sensitivity and specificity diagnostic
tools and criteria for depressive symptoms, but the PHQ-9
and the CAGE were validated in western settings and not
in the Cameroonian HIV clinic settings. Questions related
to the impact of depressive symptoms on function were not
assessed. Finally, it would be very important to evaluate
the impact of depression on the adherence to ART in
L’akoa et al. BMC Psychiatry 2013, 13:228 Page 6 of 7
http://www.biomedcentral.com/1471-244X/13/228Cameroon, since this data is completely lacking. Indeed, all
the studies on factors associated with adherence to ART in
Cameroon, surprisingly, did not assess depression [39].
Conclusions
Overall our findings indicate a high prevalence of de-
pressive symptoms in newly diagnosed HIV-infected pa-
tients in Yaoundé, Cameroon, and their association with
alcohol abuse and severe immunodepression. This high-
lights the need of efficient mental health interventions
to be integrated into routine HIV clinical care in
Cameroon. In this way, early screening and treatment of
depression must be a major objective, since it may im-
prove linkage to and retention in HIV care centers.
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